Medical Marketing & Media5d
Novo Nordisk welcomes patients to the Ozempic Era
With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.
The Financial Express6d
Novo Nordisk to launch new therapies in blood and growth disorders after success in diabetes and obesity
Martin Holst Lange, Executive Vice President, Development, Novo Nordisk, highlighted during the press briefing that their ...
Are weight-loss drugs like Ozempic a forever medicine? Vikrant Shrotriya of Novo Nordisk India reacts
As the global demand for obesity treatments skyrockets, Vikrant Shrotriya discusses the complex nature of obesity, the ...
BT Exclusive: We aim to compete cross all segments in obesity treatments, says Camilla Sylvest of Novo Nordisk
In an exclusive conversation with Business Today, Camilla Sylvest, Executive Vice President, Commercial Strategy & Corporate ...
Ozempic’s new frontier: The war on aging
Research suggests potential health benefits beyond what popular diabetes and weight-loss drugs were first approved to treat.
pharmaphorum6d
Novo Nordisk moves chronic kidney disease drug ziltivekimab into phase 3
Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal.
FiercePharma6d
With blood and growth disorder bids panning out, Novo Nordisk plots path to rare disease leadership: exec
While Novo Nordisk ... disease for some 45 years, the field has often taken a back seat to the Danish drugmaker’s bread-and-butter business developing treatments for diabetes and other common ...
pharmaphorum4d
Novo Nordisk cuts $1.3bn deal for KBP blood pressure drug
head of development at Novo Nordisk, noted that hypertension is a leading risk factor for cardiovascular events, heart failure, chronic kidney disease, and premature death. “With its expected ...